Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma

摘要: In view of evidence that growth hormone (GH) and insulin-like factors (IGF) may play a role in the development renal cell carcinoma (RCC), we investigated effects hormone-releasing (GH-RH) antagonist MZ-4-71 on proliferation human adenocarcinoma line Caki-I vitro vivo. Male nude mice bearing xenografts RCC were treated for 4 weeks with injected s.c. twice daily at dose 20 microg per animal. Tumor growth, serum, liver, tumor IGF levels IGF-I receptor concentrations membranes measured. After therapy, final volume tumors was significantly (P < 0.01) decreased to 52.6 +/- 12.3 mm3 as compared controls measured 504.2 104.1 mm3. Treatment GH-RH also reduced weight, serum GH IGF-I, liver IGF-II. High-affinity binding sites detected tumors. IGF-II stimulated cells tissue cultures. Antagonist could inhibit cells, but only high concentrations. Our findings demonstrate can RCC. exert its suppressive effect through reduction release from pituitary subsequent decrease production II by The efficacy suggests this compound be considered therapy recurrent or metastatic